Abstracts tagged "interleukins (IL)"

Abstract Number: 1805 • 2012 ACR/ARHP Annual Meeting
The Pro-Fibrotic Cytokines IL-33 and IL-13 Modulates Dermal Fibrosis Via the A2A Adenosine Receptor
Ross C. Radusky¹, Jessica L. Feig², Bruce N. Cronstein³, Andrew G. Franks Jr.⁴ and Edwin SL Chan¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine. Department of Translational Medicine, New York University School of Medicine, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ⁴Dermatology & Medicine (Rheumatology), New York University, New York, NY
Background/Purpose: We have previously demonstrated that the nucleoside adenosine mediates collagen production and induce dermal fibrosis in in vitro and in vivo models. IL–13 expression…
Abstract Number: 877 • 2012 ACR/ARHP Annual Meeting
Aberrant Expression of BAFF Receptor (BR3) in Peripheral Monocytes of Patients with Primary Sjögren’s Syndrome Impacts Abnormal Activation of BAFF Signaling Through IKK-Alphaand IKK-Beta
Keiko Yoshimoto¹, Maiko Tanaka², Masako Kojima², Hideko Ogata², Hideto Kameda¹, Katsuya Suzuki¹, Tohru Abe³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Dept Int Med Saitama Med Ctr, Saitama Medical School, Kawagoe-shi Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: B cell activating factor belonging to the TNF superfamily (BAFF) regulates proliferation, differentiation and survival of B cells and plays a pivotal role in…
Abstract Number: 2031 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin-1 Receptor Antagonist
Gina A. Montealegre¹, Adriana Almeida de Jesus², Dawn C. Chapelle³, Paul Dancey⁴, Joost Frenkel⁵, Annet van Royen-Kerkhoff⁶, Ronit Herzog⁷, Giovanna Ciocca⁸, Rafael F. Rivas-Chacon⁸, Ann M. Reed⁹, Nicole Plass³, Ivona Aksentijevich¹⁰, Polly J. Ferguson¹¹, Suvimol C. Hill¹², Edward Cowen¹³ and Raphaela T. Goldbach-Mansky³, ¹NIAMS, Bethesda, MD, ²Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁴Health Science Centre, Memorial University of Newfoundland, St Johns, Canada, ⁵Wilhelmina Childrens Hospital, University of Utrecht, Utrecht, Netherlands, ⁶University of Utrecht, Utrecht, Netherlands, ⁷Cornell University, New York, NY, ⁸Miami Children's Hospital, Miami, FL, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ¹¹Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, ¹²Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, ¹³Dermatology Consultation Servce, National Cancer Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by mutations in IL1RN gene and clinically characterized by a perinatal onset…
Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
Abstract Number: 2021 • 2012 ACR/ARHP Annual Meeting
The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome Is Driven by the Phenotype Severity Rather Than the Age
Roberta Caorsi¹, Loredana Lepore², Francesco Zulian³, Maria Alessio⁴, Achille Stabile⁵, Antonella Insalaco⁶, Martina Finetti¹, Antonella Battagliese⁴, Giorgia Martini⁷, Chiara Bibalo⁸, Alberto Martini⁹ and Marco Gattorno¹, ¹Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, ²Istituto Burlo Garofolo, Trieste, Italy, ³Department of Pediatrics, University of Padua, Padova, Italy, ⁴Department of Pediatrics,, Federico II Hospital, Napoli, Italy, ⁵DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, ⁶Department of Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Department of Pediatrics,, University of Padua, Padua, Italy, ⁸Pediatrics-Univ of Trieste, Ospedale-Infantile Trieste, Trieste, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: to identify the optimal regimen for the treatment with Canakinumab in CAPS patients and, in patients receiving both Anakinra and Canakinumab during their disease…
Abstract Number: 899 • 2012 ACR/ARHP Annual Meeting
A Role for Soluble Interleukin-6 Receptor As an Antagonist of Interleukin-27 Signaling
Misato Hashizume¹, Keiko Esaki² and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Recently, it has been reported that interleukin (IL)-27 treatment reduces inflammation and ameliorates arthritis in collagen-induced arthritis mice. IL-27 is a heterodimeric cytokine composed…
Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Hiroto Yoshida¹, Miho Suzuki¹, Misato Hashizume¹, Keisuke Tanaka², Masashi Shiina², Isao Matsumoto³, Takayuki Sumida³ and Yoshihiro Matsumoto², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, ³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
Abstract Number: 894 • 2012 ACR/ARHP Annual Meeting
Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts
A. Krabben¹, A. G. Wilson², R. Knevel¹, A. Zhernakova³, E. Brouwer³, E. Lindqvist⁴, T. Saxne⁴, G. Stoeken-Rijsbergen¹, J. A. B. van Nies¹, D. P. C. de Rooy¹, T.W.J. Huizinga¹, B. P. C. Koeleman⁵, R. E. M. Toes¹, P. K. Gregersen⁶ and A. H. M. van der Helm-van Mil¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁴Rheumatology, Lund University, Lund, Sweden, ⁵Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY
Background/Purpose: The severity of RA is reflected by the severity of radiological joint destruction. It is highly variable between patients and up to 58% of…
Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Miho Suzuki¹, Hiroto Yoshida², Misato Hashizume¹, Masashi Shiina², Keisuke Tanaka¹ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
Abstract Number: 1062 • 2012 ACR/ARHP Annual Meeting
Identification of Highly Potent and Selective Interleukin-1 Receptor-Associated Kinase 4 Inhibitors for the Treatment of Rheumatic Diseases
Divya Chaudhary¹, Shaughnessy Robinson², Craig E. Masse¹, Matthew D. Wessel², Shawn Watts², Jeremy Greenwood², Mee Shelley², Mark Brewer², Geraldine Harriman¹, Leah L. Frye², Ronald T. Wester¹, Rosana Kapeller¹ and Donna Romero¹, ¹25 First Street Suite 404, Nimbus Discovery, Inc., Cambridge, MA, ²Schrödinger, Inc., New York, NY
Background/Purpose: Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of the innate immune response orchestrated by interleukin-1 receptor (IL-1R), interleukin-18 receptor (IL-18R), IL-33…
Abstract Number: 2084 • 2012 ACR/ARHP Annual Meeting
ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Shunji Yamazaki¹, Masamichi Inami¹, Misato Ito¹, Yasutomo Fujii¹, Kaori Hanaoka¹, Kaoru Yamagami¹, Kenji Okuma¹, Yoshiaki Morita¹, Shohei Shirakami², Takayuki Inoue², Susumu Miyata³ and Yasuyuki Higashi¹, ¹Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ²Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, ³Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan
Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders…